pharmaphorum September 27, 2022
The emergence of PD-(L1) treatments has provided patients options where previously none existed, and the leading forms of these therapies have gone on to blockbuster sales. Ben Hargreaves finds that the next step to enhance these treatments further could be to find synergies with emerging therapies employing similar modes of action, such as therapeutic cancer vaccines.
Cancer treatment has seen a number of breakthroughs in recent years, whether through checkpoint inhibitor therapies, CAR-T therapies, or in the growing number of approvals of antibody drug conjugates. One area that is becoming more widely discussed with the potential to be added to this group is that of therapeutic cancer vaccines.
Unlike traditional vaccines, the new generation of cancer vaccines are delivered to...
Today's Sponsors
Today's Sponsor